Test for CD56 in newly diagnosed blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at a marker called CD56 in people who have been newly diagnosed with a blood cancer (a hematologic malignancy). The results may help doctors better understand the disease and guide future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer diagnosis (not a non-cancer blood condition).
- Your diagnosis is new (newly diagnosed).
- You do not have a blood disorder that is not a blood cancer.
- Your condition fits the trial category of “hematologic malignancy.”
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
This study looks at routine blood test results (called CBC) in people who have just been diagnosed with acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if certain blood levels can help doctors understand the disease better and guide treatment.
This study looks at two markers on blood cells (called CD38 and CD56) in people with chronic myeloid leukemia (CML). It may help doctors understand the disease better.
This study looks at certain markers on your blood cancer cells to understand them better. By joining, you help doctors learn more about your disease, which may guide future care.
This study looks at certain proteins on B-cell blood cancer cells to understand them better. It may help doctors learn more about these cancers, but it is not a treatment trial.
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.